On January 15, 2018, Swedish company XBrane Biopharma issued a press release stating that, in December 2017, it signed a non-binding letter of intent with Chinese company CR Pharma regarding XLucane, a ranibizumab biosimilar.  According to the press release, XBrane and CR Pharma intend to take Xlucane to market in China, although no terms are yet agreed-upon.  XLucane is a biosimilar candidate to Genentech’s Lucentis®, used for treatment of the wet form of age related macular degeneration.